RedHill Biopharma (RDHL) Gross Profit (2014 - 2023)

RedHill Biopharma (RDHL) has 9 years of Gross Profit data on file, last reported at $990000.0 in Q2 2023.

• Gross Profit for Q2 2023 came in at $990000.0, down 89.41% year-over-year; the trailing twelve-month figure through Jun 2023 was $15.3 million (down 51.16% YoY), and the FY2025 annual result was $5.5 million, up 13.67% from the prior year.
• Gross Profit declined to $990000.0 in Q2 2023 per RDHL's latest filing, from $2.0 million in the prior quarter.
• Over five years, Gross Profit peaked at $12.4 million in Q3 2021 and troughed at -$659000.0 in Q1 2020.
• A 5-year average of $5.5 million and a median of $5.5 million in 2020 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2020 and 2021: Gross Profit sank 149.92% in 2020, then soared 1666.31% in 2021.
• A 5-year view of Gross Profit shows it stood at $802000.0 in 2019, then soared by 1247.76% to $10.8 million in 2020, then sank by 74.68% to $2.7 million in 2021, then jumped by 53.45% to $4.2 million in 2022, then sank by 76.43% to $990000.0 in 2023.
• Business Quant data shows RDHL's Gross Profit at $990000.0 in Q2 2023, $2.0 million in Q1 2023, and $4.2 million in Q4 2022.